Irreversible airway obstruction in asthma
- PMID: 19210908
- DOI: 10.1007/s11882-009-0025-2
Irreversible airway obstruction in asthma
Abstract
Asthma is generally characterized by fully reversible airway obstruction. However, a significant proportion of asthma patients demonstrate an incomplete reversibility of airway obstruction (IRAO) despite optimal treatment and the absence of a significant smoking history. Such partially irreversible airway obstruction may be due to residual airway inflammation, particularly of the eosinophilic type, and structural changes. Risks factors for IRAO include reduced pulmonary function early in life, frequent exacerbations, smoking, continuing exposure to a sensitizing agent, and adult-onset asthma. IRAO is associated with increased disease severity and increased asthma-related morbidity and mortality. Optimal asthma control, including prevention of asthma exacerbations, smoking avoidance, and sufficient anti-inflammatory therapy, should be implemented in an effort to avoid an accelerated decline in lung function and the development or worsening of IRAO.
Similar articles
-
Clinical and biological factors associated with irreversible airway obstruction in adult asthma.Respir Med. 2020 Dec;175:106202. doi: 10.1016/j.rmed.2020.106202. Epub 2020 Nov 10. Respir Med. 2020. PMID: 33202369
-
Comparative prevalence of co-morbidities in smoking and non-smoking asthma patients with incomplete reversibility of airway obstruction, non-smoking asthma patients with complete reversibility of airway obstruction and COPD patients.Respir Med. 2017 Apr;125:82-88. doi: 10.1016/j.rmed.2017.03.005. Epub 2017 Mar 6. Respir Med. 2017. PMID: 28340867
-
Airway inflammation in asthma with incomplete reversibility of airflow obstruction.Respir Med. 2003 Jun;97(6):739-44. doi: 10.1053/rmed.2003.1491. Respir Med. 2003. PMID: 12814164
-
Risk factors associated with irreversible airflow limitation in asthma.Curr Opin Allergy Clin Immunol. 2008 Feb;8(1):63-9. doi: 10.1097/ACI.0b013e3282f3b5b5. Curr Opin Allergy Clin Immunol. 2008. PMID: 18188020 Review.
-
Inhaled steroids and airway remodelling in asthma.Acta Biomed. 2003 Dec;74(3):121-5. Acta Biomed. 2003. PMID: 15055015 Review.
Cited by
-
μ-chain-deficient mice possess B-1 cells and produce IgG and IgE, but not IgA, following systemic sensitization and inhalational challenge in a fungal asthma model.J Immunol. 2012 Aug 1;189(3):1322-9. doi: 10.4049/jimmunol.1200138. Epub 2012 Jun 25. J Immunol. 2012. PMID: 22732592 Free PMC article.
-
Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3.J Allergy Clin Immunol. 2021 Sep;148(3):752-762. doi: 10.1016/j.jaci.2021.01.029. Epub 2021 Feb 9. J Allergy Clin Immunol. 2021. PMID: 33577895 Free PMC article.
-
Prevalence and factors associated with asthma among adolescents and adults in Uganda: a general population based survey.BMC Public Health. 2019 Feb 22;19(1):227. doi: 10.1186/s12889-019-6562-2. BMC Public Health. 2019. PMID: 30795752 Free PMC article.
-
Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2018 Feb;36(2):131-144. doi: 10.1007/s40273-017-0571-8. Pharmacoeconomics. 2018. PMID: 28933002 Review.
-
Fms-like tyrosine kinase 3 ligand decreases T helper type 17 cells and suppressors of cytokine signaling proteins in the lung of house dust mite-sensitized and -challenged mice.Am J Respir Cell Mol Biol. 2010 Nov;43(5):520-9. doi: 10.1165/rcmb.2009-0241OC. Epub 2009 Nov 20. Am J Respir Cell Mol Biol. 2010. PMID: 19933379 Free PMC article.